Virios therapeutics highlights safety data from phase 2a fibromyalgia trial at the international association for the study of pain (iasp) world congress

Atlanta--(business wire)---- $viri #iasp2021--virios therapeutics, inc. (nasdaq: viri), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced today that data from the company's phase 2a clinical trial prid-201 demonstrated that imc-1 was better tolerated than placebo in patients with fibromyalgia (“fm”). this result is highlighted in a poster presentation at the international association fo
VIRI Ratings Summary
VIRI Quant Ranking